# Melanotans

Sonoran UV Biology · Clinical & Regulatory Field Report

**Directory:** [Tucson Origin](/tucson-origin) · [Five Receptors](/five-receptors) · [Scenesse](/afamelanotide-scenesse) · [Vyleesi](/bremelanotide-vyleesi) · [Imcivree](/setmelanotide-imcivree) · [Online Market](/melanotan-online-market) · [Case Reports](/case-reports-and-safety) · [Regulators](/regulatory-warnings) · [References](/references) · [About](/about)

**Clinical Case Reports · Systemic Events, Moles & Causality** · Dispatch 07 · Safety Evidence

---

[Melanotans](/) / Case Reports & Safety

# Priapism, rhabdomyolysis, and darkening moles: What case reports show — and cannot prove

Melanotan II activates four human melanocortin receptors without clinical screening or verified dosing. Hospital and dermatology case reports document severe acute diagnoses alongside pigmented lesions that require careful causal interpretation.

**Field Record 09 · Pigment Ledger:** MC1R activation shifts melanocytes toward [dark photoprotective eumelanin over free-radical-generating red pheomelanin](https://pubmed.ncbi.nlm.nih.gov/7581459/), yet rapid mole darkening [complicates clinical presentation of pigmented lesions](https://pubmed.ncbi.nlm.nih.gov/20545686/).

## Multi-receptor pharmacology and the scope of published safety evidence

In human-receptor assays compiled by [Yuan & Tao (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9599618/) (Kievit et al., 2013), **Melanotan II** activates `MC1R` (0.2 nM), `MC3R` (0.51 nM), `MC4R` (0.05 nM), and `MC5R` (5.33 nM) with nanomolar to subnanomolar potency. As [Böhm et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11664455/) note, because Melanotan II can cross the blood–brain barrier and is nonselective, it activates other melanocortin receptors, yielding events such as fatigue, loss of appetite, and penile erection.

In a February 2026 PRISMA systematic review of [68 peer-reviewed studies across self-tanning agents—dihydroxyacetone (DHA), melanotan, forskolin, and carotenoids](https://pubmed.ncbi.nlm.nih.gov/41890775/)—Resnick et al. (2026) reported **rhabdomyolysis**, **renal infarction**, and **priapism** in their discussion of unregulated melanotan I and II use. Because online melanotan products are [unlicensed and incompletely tested](https://pubmed.ncbi.nlm.nih.gov/24355990/), published human safety data come mainly from individual clinical case reports and dermatologic case series—records that document severe clinical diagnoses presenting after exposure but cannot establish population incidence rates.

## Acute systemic, urologic, vascular, and oral mucosal case reports

- **Sympathomimetic toxidrome and rhabdomyolysis:** In a single-patient emergency-department case report, [Nelson et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23121206/) described a **39-year-old man** arriving two hours after exposure to internet-purchased Melanotan II (confirmed as Melanotan II by mass spectrometry against a reference standard). Exam showed restlessness, anxiety, mydriasis, diaphoresis, diffuse muscle tremors, blood pressure **151/85 mmHg**, and heart rate **130 bpm peaking at 146 bpm**; hospital diagnostic laboratory values showed creatinine **2.25 mg/dL**, troponin **0.23 ng/mL**, white blood cells **19.1 k/μL**, and creatine phosphokinase (CPK) climbing from **1,760 IU/L** to **17,773 IU/L** 12 hours into ICU admission. Treated with intravenous fluids and sodium bicarbonate over a **3-day ICU stay**, his diagnostic CPK fell to **2,622 IU/L** and creatinine improved to **1.23 mg/dL** at discharge; the authors diagnosed apparent sympathomimetic symptoms, rhabdomyolysis, and renal dysfunction resulting from Melanotan II use.
- **Ischemic priapism with lasting dysfunction:** [Dreyer et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30796078/) diagnosed **low-flow priapism** in an adult male presenting after melanotan exposure; managed with cavernosal aspiration, irrigation, and phenylephrine, he avoided surgical shunting but had not recovered erectile function at **4-week follow-up**. Separately, [Mallory et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7930850/) diagnosed refractory ischemic priapism in a **55-year-old man** arriving with a **30-hour** painful erection after Melanotan II exposure; after failing bedside phenylephrine, he underwent operative **penoscrotal decompression** and had corpora fibrosis and new-onset erectile dysfunction (rigidity **4/10**) at **15-week follow-up**.
- **Renal infarction and PRES:** [Peters et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31953620/) reported a clinical diagnosis of **renal infarction**, which the authors most likely attributed to Melanotan II while noting possible thrombotic pharmacological influence and direct renal parenchymal toxicity. [Kaski et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23648958/) reported **posterior reversible encephalopathy syndrome (PRES)** alongside melanotan exposure—an event also cited in [FDA's April 22, 2026 compounding safety text](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks), while [Australia's TGA (January 24, 2025)](https://www.tga.gov.au/news/blog/dont-risk-using-tanning-products-containing-melanotan) notes: "With melanotan-II, there have been reports of increased moles and freckles, kidney dysfunction and swelling of the brain."
- **Oral mucosal pigmentation:** [Bonchev (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12942211/) examined a patient after 64 days of Melanotan II exposure and diagnosed brown pigmentation on the attached maxillary and mandibular gums (gingiva) plus irregular patches on both inner cheeks (buccal mucosa). Because the oral cavity is largely shielded from UV radiation, the authors considered systemic melanocortin activity a possible explanation for the discoloration; follow-up documented cheek pigmentation that nearly disappeared at one month and less intense gum pigmentation at three months.

### Selected Peer-Reviewed Clinical Case Reports Following Melanotan Exposure

| Clinical Diagnosis | Case Profile & Attribution | Recorded Markers & Follow-Up | Primary Source |
|---|---|---|---|
| Sympathomimetic symptoms & rhabdomyolysis | Single case report: 39-year-old man; MS-confirmed MT-II | Hospital vitals & diagnostic lab values: HR 146 bpm, BP 151/85 mmHg, creatinine 2.25 mg/dL, peak CPK 17,773 IU/L; 3-day ICU | [Nelson et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23121206/) |
| Refractory ischemic priapism | 55-year-old man; onset after MT-II exposure | 30-hour duration; penoscrotal decompression; fibrosis & ED at 15 wk | [Mallory et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7930850/) |
| Low-flow priapism | Adult male ED presentation after melanotan | Aspiration, irrigation & phenylephrine; ED unresolved at 4 wk | [Dreyer et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30796078/) |
| Renal infarction | Single case; most likely attributed to MT-II | Possible thrombotic or direct parenchymal mechanism proposed | [Peters et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31953620/) |
| Oral mucosal pigmentation | 64-day MT-II exposure; systemic activity proposed | Cheek pigment nearly gone at 1 mo; less intense gum pigment at 3 mo | [Bonchev (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12942211/) |
| Five primary melanomas in situ | 49-year-old man (Fitzpatrick II); MT-II + ~12 sunbed sessions; causality unproven | Histology confirmed 5 melanomas in situ in severely dysplastic nevi | [Vadner & Smith (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13279914/) |

## Darkening moles and the melanoma causality audit

**First, unregulated use alters pigmented lesions.** Reviews note case reports linking unregulated Melanotan I and II to [melanocytic changes in existing moles and newly emerging dysplastic nevi](https://pubmed.ncbi.nlm.nih.gov/28266027/), complicating skin exams ([Langan et al., 2010](https://pubmed.ncbi.nlm.nih.gov/20545686/)).

**Second, melanoma diagnoses reported after Melanotan II carry major confounders.** [Habbema et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28266027/) summarized four reports of melanomas emerging from existing moles during or shortly after melanotan use, including a [20-year-old Fitzpatrick II woman combining 3 to 4 weeks of MT-II with sunbed tanning](https://pubmed.ncbi.nlm.nih.gov/24355990/). [Böhm et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11664455/) counted at least five melanoma reports during or after Melanotan II—all with other risk factors such as fair skin, excess sun or tanning-bed use, or family history, including a 23-year-old red-haired woman with three melanomas whose genetic testing revealed **heterozygous gene variants in `MC1R` and `CDKN2A`, a high-risk melanoma-associated gene**. In 2026, [Vadner & Smith (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13279914/) diagnosed **five primary melanomas in situ** in a 49-year-old Fitzpatrick II man who paired online Melanotan II with about **12 tanning-bed sessions** and anabolic hormone use.

**Third, single observational cases cannot prove causation.** [Vadner & Smith (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13279914/) note that rapid pigment darkening can unmask preexisting melanomas, frequent tanning-bed exposure is a major independent confounder, and online product composition and purity were unverified. Conversely, [Böhm et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11664455/) (disclosing Rhythm Pharmaceuticals editorial support) report that **more than 1,000 patients** exposed to prescription afamelanotide—many for **5 years** and some for **over 10 years**—had no melanoma events reported, while cautioning that chronic `MC1R` activation does not serve as complete prevention.

### Dated UV and U.S. compounding records
[Australia's TGA (January 24, 2025)](https://www.tga.gov.au/news/blog/dont-risk-using-tanning-products-containing-melanotan) states: "Use of melanotan to increase skin pigmentation artificially will not protect against UV exposure the way a suitable sunscreen will." On U.S. compounding, [FDA's bulk drug substances safety page (content current as of April 22, 2026)](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) states: "Melanotan II: Compounded drugs containing Melanotan II may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities. Published case reports discuss serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism." Alongside it, [HHS's October 30, 2026 Federal Register notice (91 FR 68526)](https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances) states its draft 503A policy "does not establish any rights for any person and is not binding on HHS or the public," and the [draft policy text](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf) states: "Therefore, to expand and improve patient access while FDA reviews these substances, in the circumstances below, HHS does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a bulk drug substance in Appendix A." Appendix A lists six substances—BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500—and omits Melanotan II.

---

## Safety Audit · Case Record

- **Evidence Scope:** 68-study tanning-agent review (Resnick, 2026), individual hospital case reports, and dermatology case series
- **Acute Diagnoses:** Sympathomimetic symptoms, rhabdomyolysis & renal dysfunction (Nelson et al., 2012); 30-hour ischemic priapism (Mallory et al., 2021); renal infarction (Peters et al., 2020); PRES (Kaski et al., 2013)
- **Oral Follow-Up:** Cheek pigmentation that nearly disappeared at one month and less intense gum pigmentation at three months (Bonchev, 2026)
- **Melanoma Audit:** At least five reports during/after MT-II, all confounded by fair skin, tanning beds, or genetic variants; single cases cannot prove causation

### Related Field Dispatches
- [06. Online Melanotan I & II: Lab Assays](/melanotan-online-market)
- [08. Regulatory Records From Six Jurisdictions](/regulatory-warnings)
- [03. Afamelanotide (Scenesse)](/afamelanotide-scenesse)
- [04. Bremelanotide (Vyleesi)](/bremelanotide-vyleesi)

- Previous Dispatch · 06: [Online Melanotan I & II: Lab Assays](/melanotan-online-market)
- Next Dispatch · 08: [Regulatory Records From Six Jurisdictions](/regulatory-warnings)

---

**Melanotans** is an independent educational pharmacology field report on melanocortin receptor biology, prescription medicines afamelanotide (Scenesse), bremelanotide (Vyleesi), and setmelanotide (Imcivree), and online products sold as Melanotan I and II—not a laboratory, manufacturer, clinic, pharmacy, telehealth service, or seller, and never medical advice.

- Plain-text edition: [case-reports-and-safety.md](/case-reports-and-safety.md) · Full bibliography: [Primary Source Ledger](/references)
- Pathway & Prescription Medicines: [Tucson Origin](/tucson-origin) · [Five Receptors](/five-receptors) · [Afamelanotide (Scenesse)](/afamelanotide-scenesse) · [Bremelanotide (Vyleesi)](/bremelanotide-vyleesi) · [Setmelanotide (Imcivree)](/setmelanotide-imcivree)
- Online Market, Safety & Charter: [Online Market & Lab Assays](/melanotan-online-market) · [Case Reports & Safety](/case-reports-and-safety) · [Regulatory Warnings](/regulatory-warnings) · [References](/references) · [About](/about) · [Contact](/contact)
